The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
 
Employment - BostonGene
Leadership - BostonGene
Stock and Other Ownership Interests - BostonGene
Consulting or Advisory Role - Celgene; Gilead Sciences; Roche
Research Funding - Celgene; Gilead Sciences; Roche
Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.
 
Irina Zhuk
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
 
Anna Novokreschchenova
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
 
Aida Aukhadieva
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
 
Sandrine Degryse
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
Patents, Royalties, Other Intellectual Property - BostonGene
 
Aleksei Shevkoplias
Employment - BostonGene
 
Anna Belozerova
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
 
Krystle Nomie
No Relationships to Disclose
 
Nikita Kotlov
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
Patents, Royalties, Other Intellectual Property - BostonGene
 
Georgy Sagaradze
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
Patents, Royalties, Other Intellectual Property - BostonGene
 
Lev Bedniagin
Employment - BostonGene
 
Linda Balabanian
Employment - BostonGene
 
Ekaterina Postovalova
No Relationships to Disclose
 
Alexander Bagaev
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
Patents, Royalties, Other Intellectual Property - BostonGene
 
Nathan Fowler
No Relationships to Disclose
 
J Andrew Andrew Livingston
Consulting or Advisory Role - Foghorn Therapeutics
Research Funding - Repare Therapeutics (Inst)
Other Relationship - Guidepoint Global
 
Vinod Ravi
Stock and Other Ownership Interests - AstraZeneca; Merck; Moderna Therapeutics; Pfizer; TRACON Pharma
Honoraria - UpToDate
Consulting or Advisory Role - AADi; Daiichi Sankyo; Gerson Lehrman Group; Guidepoint Inc
Research Funding - AADi (Inst); Athenex (Inst); Novartis (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Gregory Michael Cote
Consulting or Advisory Role - BioAtla; C4 Therapeutics; Daiichi Sankyo/UCB Japan; Eisai; Foghorn Therapeutics; Ikena Oncology
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)